BioWorld

Jan. 23, 2004

Bringing In IL13 Phase III Trial Support, NeoPharm Gets $68.4M

NeoPharm Inc. intends to use proceeds from a $68.4 million public offering to advance its cancer agent for malignant glioma. (BioWorld Today) Read More

Genaera Gains $20M Through Direct Stock Equity Placement

Childhood Brain Tumor Growth With Neurofibromatosis Needs Abnormal Cellular Neighbors In Mouse Model

NIH Director In Senate Hot Seat Over Employee Disclosure Rules

Other News To Note

Today's news in brief

BioWorld

BioWorld briefs for Feb. 2, 2025.

Today's news in brief

Briefs

BioWorld MedTech briefs for Jan. 30, 2026.

Centessa’s CNT-9982 shows promise for MDD

BioWorld Science

Orexin OX2 receptor agonists have demonstrated the ability to enhance wakefulness in rodent models, as well as in nonhuman primates and patients with narcolepsy...

First-in-class ADC targeting DEM-TXX shows high preclinical efficacy

BioWorld Science

Researchers at DEM Biopharma Inc. reported preclinical findings demonstrating the efficacy of DEM-301, a bifunctional antibody-drug conjugate (ADC) engineered to...

Illustration of brain with neuron receptor

5-HT2R allosteric ligands attenuate cocaine use and seeking behavior

BioWorld Science

Serotonergic G-protein-coupled receptors (GPCRs), including the 5-HT2A receptor (5-HT2AR) and 5-HT2CR, are key regulators of cortical signaling pathways and...